ICYMI: GX-03 Hits 92.6% EASI-50 at Week 4

Turn Therapeutics recently released interim phase 2 data for GX-03, an investigational extended-release topical therapy for moderate to severe atopic dermatitis (AD), and the early findings offer a potentially meaningful addition to a treatment landscape that advanced practice providers navigate daily. The 50-subject interim cohort — reviewed under an independent data monitoring committee (IDMC) — showed numerically higher EASI response rates for GX-03 versus vehicle at both week 4 and week 8, with no treatment-related safety signals reported.¹

“What became increasingly apparent during the interim review was the speed with which responses emerged,” said Bradley Burnam, chief executive officer of Turn Therapeutics, in a news release. “The review identified opportunities to refine enrollment criteria and endpoint selection while providing valuable insight into where GX-03 activity appears most visible. The consistency of response across earlier efficacy measures suggests clinically meaningful improvement may emerge sooner than originally anticipated, which could have important implications for both future regulatory strategy and patient outcomes.”

Responder Rates: What the Numbers Look Like in Practice

For clinicians managing moderate to severe AD, EASI thresholds translate directly to what patients experience in the exam room. At week 4, 92.6% of GX-03-treated subjects achieved EASI-50 — at least a 50% reduction in overall eczema severity — compared with 65.2% in the vehicle arm. At the near-clearance threshold, EASI-90 rates were 44.4% for GX-03 versus 30.4% for vehicle at week 4, continuing to climb to 51.9% versus 34.8% by week 8. That progressive deepening of response through week 8 is a pattern worth noting: it suggests that patients who respond early may continue to improve with continued use, a dynamic relevant to treatment planning and follow-up scheduling.

No treatment-related serious adverse events, tolerability concerns, or discontinuations were reported during the interim period — a profile that may appeal in practice settings where patient-reported tolerability directly affects adherence.

Understanding GX-03's Mechanism

GX-03 works differently from the biologics and JAK inhibitors that currently anchor moderate to severe AD management. Rather than targeting specific upstream cytokine pathways — as dupilumab does with IL-4/IL-13, or upadacitinib does with JAK1 — GX-03 is designed to deliver sustained localized exposure to polyhexanide, an antiseptic agent with established use in wound care, directly at the skin surface.² The proposed mechanism involves modulation of inflammatory signaling within the skin microenvironment itself, though detailed mechanistic data in AD has not yet been published through regulatory-grade studies.

If later-stage data continue to support efficacy and safety, GX-03 could represent a topical option for patients who are not candidates for systemic therapy, who have failed or declined injectables, or who are seeking a localized approach to disease management.

Trial Design Context and Limitations to Know

The vehicle response rate in this interim cohort — 65.2% achieving EASI-50 at 4 weeks — is notably higher than what is typically seen in comparable AD trials, where placebo arms generally fall in the 30% to 45% range. Turn Therapeutics acknowledged this, attributing it in part to less stringent baseline enrollment controls around EASI scores and body surface area involvement. The company has since refined enrollment criteria for the second stage of the trial to better align with standard AD study design.

The treatment-versus-vehicle separation is clinically directional, but the elevated vehicle rates compress the observed difference and make it harder to draw firm conclusions about absolute efficacy at this stage. Enrollment is ongoing and nearing completion of the originally planned sample size.

Regulatory and Clinical Outlook

Turn Therapeutics is preparing to request an FDA meeting to discuss regulatory strategy and potential development pathways following trial completion. Dermatology expert Stephen Bresnick, MD — who recently co-authored a peer-reviewed paper on GX-03's proposed mechanism — noted that early disease control has meaningful implications for both disease burden and quality of life, and cited the favorable safety profile alongside rapid responder activity as supportive of continued development.

Detailed phase 2 interim findings are scheduled for presentation at the Jefferies Global Healthcare Conference on June 4, 2026. For clinicians tracking the AD pipeline, GX-03 is a topical candidate worth watching — particularly as the field continues to seek options that expand beyond systemic immunomodulation.

References

1. Turn Therapeutics reports interim analysis findings and adaptive optimization strategy from phase 2 GX-03 trial in moderate-to-severe atopic dermatitis. News release. Turn Therapeutics. Published June 1, 2026. Accessed June 1, 2026. https://www.businesswire.com/news/home/20260601276401/en/Turn-Therapeutics-Reports-Interim-Analysis-Findings-and-Adaptive-Optimization-Strategy-from-Phase-2-GX-03-Trial-in-Moderate-to-Severe-Atopic-Dermatitis
2. Calabrese L, D'Onghia M, Lazzeri L, Rubegni G, Cinotti E. Blocking the IL-4/IL-13 axis versus the JAK/STAT pathway in Atopic Dermatitis: How Can We Choose?. J Pers Med. 2024;14(7):775. Published 2024 Jul 22. doi:10.3390/jpm14070775